

Singapore's K2 Therapeutics appoints new CEO and announces \$50 M Seed Financing

August 14, 2026 | News

Seed financing completed to support development of a growing portfolio of first- and best-in-class therapeutic candidates



Singapore-based biotech startup K2 Therapeutics has announced the appointment of Dr Ying Huang as Chief Executive Officer (CEO). K2 was founded with \$50 million in seed financing from MPM BioImpact.

Founded by MPM BioImpact in 2024, K2 is advancing a new model for biotechnology innovation, combining worldwide asset sourcing and experienced drug development leadership to identify and advance high-potential first-in-class and best-in-class therapeutic candidates. The seed financing has supported the expansion of the Company's portfolio and advancement of its globally sourced assets.

Dr Huang brings more than two decades of experience spanning biotechnology research and development, corporate strategy, capital markets, and company leadership. Most recently, he served as Chief Executive Officer and member of the Board of Directors at Legend Biotech, where he helped lead the global development and commercialisation of innovative cell therapies, including CARVYKTI®, one of the first commercially successful China-to-U.S. drug launches with annual sales exceeding \$2 billion. He also oversaw Legend's evolution into a fully integrated global biopharmaceutical company with more than 3,000 employees spanning R&D, GMP manufacturing, and commercial operations.

K2 is building a diversified portfolio of innovative therapeutics by identifying promising opportunities globally and advancing them through focused drug development. The company's portfolio now includes eight therapeutic programs spanning multiple modalities, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), with programs ranging from preclinical development to clinical-stage.